RBC Capital raised Medtronic’s price target to $118 from $111, maintaining an Outperform rating. Q2 results showed a 1.0% beat on sales and 3.8% on EPS due to strong cardiovascular performance. The company expects similar growth in Q3 and to exit the FY at 6%, confirming RBC’s growth acceleration thesis.

Source: TheFly

For more information on MDT, visit the Disclaimer & Disclosure and Report an Issue pages on TipRanks.

Read more at Yahoo Finance: Medtronic price target raised to $118 from $111 at RBC Capital